Alveron Pharma

Alveron Pharma is a private, pre-clinical stage biotech focused on revolutionizing the treatment of life-threatening bleeds caused by anticoagulants. Its lead candidate, OKL-1111, is a synthetic, universal reversal agent designed for rapid administration in emergencies like hemorrhagic stroke, potentially cutting treatment delays from over an hour to minutes. The company is backed by European venture capital and leverages a management team with deep experience in coagulation therapeutics and drug development.

A unique coagulation platform based on a synthetic cyclodextrin molecule engineered to universally bind and neutralize a wide range of anticoagulant and antiplatelet drugs, enabling rapid reversal without requiring prior drug identification.

Total raised: $22M

Competes against specific reversal agents (e.g., Andexxa, Praxbind) and non-specific options (PCC, Vitamin K). Key differentiation is OKL-1111's universal mechanism against multiple anticoagulant/antiplatelet classes, ready-to-use formulation for speed, and a synthetic cyclodextrin platform with a potentially favorable safety profile.